Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer

Lung Cancer

Volumn 68, Issue 1, 2010, Pages 78-83

  Funai, Kazuhito ^a,b   Takamochi, Kazuya ^b   Itaya, Toru ^b   Mochizuki, Takahiro ^b   Nakamura, Toru ^c   Toyoda, Futoru ^c   Yong Il, Kim ^d   Sasaki, Kazuyoshi ^a   Momiki, Shigeru ^a   Takahashi, Tsuyoshi ^e   Neyatani, Hiroshi ^e   Suzuki, Kazuya ^b  

^a HAMAMATSU MEDICAL CENTER   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Division of General Thoracic Surgery   (Japan)

^d SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^e FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

Author keywords

Adjuvant chemotherapy; Chemotherapy compliance; Gemcitabine; Non small cell lung cancer; Split dose cisplatin; Treatment compliance

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HICCUP; HUMAN; JAPANESE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PATIENT COMPLIANCE; PNEUMONECTOMY; PROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 77649186734     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.05.018     Document Type: Article

References (28)

1. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
2. Goya T., Asamura H., Yoshimura H., Kato H., Shimokata K., Tsuchiya R., et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50 (2005) 227-234
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
4. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
5. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
6. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
7. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26 (2008) 3552-3559
8. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of 5 randomized trials including 4584 patients. J Clin Oncol 24 (2006) 366S [abstr. 7008]
9. Strauss G.M., Herndon II J.E., Maddaus M.A., Johnstone D.W., Johnson E.A., Harpole D.H., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26 (2008) 5043-5051
10. Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., and Peters G.J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2 (1996) 521-530
11. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., and Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 (1995) 72-79
12. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80
13. Vogl S.E., Berenzweig M., Camacho F., Greenwald E., and Kaplan B.H. Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinoma. Cancer 50 (1982) 24-26
14. Wilke H., Achterrath W., Schmoll H.J., Gunzer U., Preusser P., and Lenaz L. Etoposide and split-dose cisplatin in small-cell lung cancer. Am J Clin Oncol 11 (1988) 572-578
15. Gandara D.R., DeGregorio M.W., Wold H., Wilbur B.J., Kohler M., Lawrence H.J., et al. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer. J Clin Oncol 4 (1986) 1787-1793
16. Gandara D.R., Wold H., Perez E.A., Deisseroth A.B., Doroshow J., Meyers F., et al. Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 81 (1989) 790-794
17. Kim J.H., Lee D.H., Shin H.C., Kwon J.H., Jung J.Y., Kim H.J., et al. A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. Lung Cancer 54 (2006) 57-62
18. Nagourney R.A., Brewer C.A., Radecki S., Kidder W.A., Sommers B.L., Evans S.S., et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 88 (2003) 35-39
19. Nagourney R.A., Link J.S., Blitzer J.B., Forsthoff C., and Evans S.S. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 18 (2000) 2245-2249
20. Hussain S.A., Stocken D.D., Riley P., Palmer D.H., Peake D.R., Geh J.I., et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 91 (2004) 844-849
21. Shepherd F.A., Cormier Y., Burkes R., Evans W.K., Goss G., Klimo P., et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 24 (1997) S8-27-S8-30
22. Berardi R., Porfiri E., Scartozzi M., Lippe P., Silva R.R., Nacciarriti D., et al. Elderly patients with advanced non-small cell lung cancer. A phase II study with weekly cisplatin and gemcitabine. Oncology 65 (2003) 198-203
23. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18 (2007) 317-323
24. Hamada C., Tanaka F., Ohta M., Fujimura S., Kodama K., Imaizumi M., et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23 (2005) 4999-5006
25. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
26. Strauss G.M., Herndon J., Maddaus M.A., Johnstone D.W., Johnson E.A., Watson D.M., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 22 Suppl. (2004) 621S [abstr 7019]
27. Strauss G.M., Herndon J., Maddaus M.A., Johnstone D.W., Johnson E.A., Watson D.M., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and leukemia Group B protocol 9633. J Clin Oncol 24 (2006) 365S [abstr 7007]
28. Alam N., Shepherd F.A., Winton T., Graham B., Johnson D., Livingston R., et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer 47 (2005) 385-394